8-K filing — Polaryx Therapeutics, Inc. (PLYX)
Filed: 2026-09-01 AccNo: 0001213900-26-096235 Size: 218 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
LUCID CAPITAL MARKETS Initiates Coverage On Polaryx Therapeutics with Buy Rating, Announces Price Target of $7
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Polaryx Therapeutics (NASDAQ:PLYX) with a Buy rating and announces Price Target of $7.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Polaryx Therapeutics Says It Remains On Track To Initiate Phase 2 SOTERIA Basket Trial Of PLX-200 In Four Pediatric Lysosomal Storage Disorders In Q4 2026
Polaryx Therapeutics shares are trading higher after Raymond James initiated coverage on the stock with a Strong Buy rating and announced a $6 price target.
This Vail Resorts Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday
Wall Street analysts changed outlook on top names. Check analyst ratings page for all changes. See what analysts think of MTN stock.